-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175

Benzinga·08/10/2026 18:53:08
Listen to the news
JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.